Rita Ghosh, Ph.D.

Dr. Rita Ghosh received her MS and PhD in Life Sciences at the University of Hyderabad in 1984 and 1990, respectively.  She completed postdoctoral training in molecular biology and molecular cancer biology at both Texas A&M University and MD Anderson Cancer Center.  She joined the faculty of the Department of Urology in 2011.  Dr. Ghosh’s laboratory researches gene-environment interactions that lead to oxidative stress in cancer and to develop ways to target those deregulated signaling pathways for cancer prevention/therapy.  Dr. Ghosh’s lab uses a variety of cell culture and animal models (immunocompromised and transgenic rodents) with a combination of genetic, biochemical and molecular biology approaches to study cancers including melanoma, bladder and prostate cancers. Her team has created many derivatives of such compounds to test structure-activity of compounds for potential anti-cancer activities.

• Professional Background

  Education

  • 1990 - PhD - Life Science - School of Life Sciences, University of Hyderabad
  • 1984 - MS - Life Science - School of Life Sciences, University of Hyderabad
  • Postdoctoral Training - Molecular Cancer Biology - MD Anderson Cancer Center
  • Postdoctoral Training - Molecular Biology - Texas A&M University

  Appointments

  • 9/2011 - Tenured Associate Professor - UTHSCSA, Urology, San Antonio

• Instruction & Training

  • 8/2013 - Present, Membership on Supervising Committee, UTHSCSA
  • 8/2012 - Present, Pre-Doctoral Student Supervision, UTHSCSA
  • 8/2012 - Present, Pre-Doctoral Student Supervision, UTHSCSA
  • 3/2011 - Present, Post-Doctoral Student Supervision, UTHSCSA
  • 7/2006 - Present, Individual Instruction, UTHSCSA

• Research & Grants

  Cancer Prevention, Cutaneous Cancer, Genitourinary Cancer

  Experimental and Developmental Therapeutics Program

  Research profile

  Grants

  State

  Funding Agency Cancer Prevention Research Institute of Texas Title RP150166 Status Active Period 3/2015 - 2/2018 Role Co-Investigator Grant Detail  

• Publications

  Abstract

  Hambright HG., Kumar AP., Ghosh R. Inhibition of melanoma cell survival through p62/LC3B autophagic signaling; 2016 Jan. (Proceedings of the American Association for Cancer Research). Hambright HG., Kumar AP., Ghosh R. Therapeutic targeting of redox-autophagy interplay as a strategy for melanoma management (Gordon Research Conference: Oxidative Stress & Disease); 2015 Jan. Suleman S. Hussain, Paul Rivas, Roble Bedolla, Nikos Papanikolaou, Robert L. Reddick, Brad H. Pollock, Daniel C. Chan, Rita Ghosh and Addanki P. Kumar. Downregulation of ribosomal protein rpS6 overcomes radioresistance in prostate cancer; 2015 Jan. (Proceedings of the American Association for Cancer Research). Mukherjee N., Ghosh R. A novel mechanism of NFkB regulation in bladder cancer; 2015 Jan. (Proceedings of the American Association for Cancer Research).

  Book Chapter

  Hussain SS., Patel D., Ghosh, R. Kumar AP. Extracting the Benefit for Cancer Prevention. In: Kumar AP.,Hussain SS., Ghosh, R. Current Pharmacology Reports. Springer: Springer Science; 2015.

  Journal Article

  Jingjing Gong, Amanda R Mu?oz, Florastina Payton-Stewart, Daniel E Chan, James W Freeman, Rita Ghosh, and Addanki P Kumar. Downregulation of STAT3/NF-κB potentiates gemcitabine activity in pancreatic cancer cells Molecular Carcinogenesis 2017 Jan;56:402-411. Ghosh R, Rivas P, Li G, Smith ML, Hawes ML, Bedolla R, Lucia MS, Reddick RL, and Kumar AP. Inhibition of prostatic intraepithelial neoplalsia as a prostate cancer prevention strategy (under preparation) 2017 Jan;. Mukherjee N, Cardenas E, Bedroll RG, and Ghosh R. SETD6 regulates NF-κB signaling in urothelial cell survival: Implications for bladder cancer Oncotarget 2017 Jan;8(9):15114-15125. Peng Meng, Roble G Bedolla, Huiyoung Yun, James E Fitzpatrick, Addanki P Kumar, Rita Ghosh. E2F1 suppresses Myosin Light Chain Kinase to regulate cytoskeletal changes associated with melanoma progression (under preparation) 2017 Jan;. Hambright HG, Batth IS, Xie J, Ghosh R, Kumar AP. Palmatine inhibits growth and invasion in prostate cancer cell: Potential role for rpS6/NFκB/FLIP Molecular Carcinogenesis 2015 Jan;54(10):1227-1234. Hambright HG, Meng P, Kumar AP, Ghosh R,. Inhibition of PI3K/AKT/mTOR axis disrupts oxidative stress-mediated survival of melanoma cells Oncotarget 2015 Jan;6(9):7195-7208. Thapa D, Meng P, Bedolla RG, Reddick RL, Kumar AP AND Ghosh R. NQO1 suppresses NF-kB-p300 interaction to regulate inflammatory mediators associated with prostate tumorigenesis Cancer Research 2014 Jan;74(5644):5644-5655.

  Review Article

  Hambright HG., Ghosh R. Autophagy: In the cROSshairs of melanoma therapeutics? BioChemical Pharmacology 2017 Jan;126:13-22. Suleman S Hussain, Addanki P Kumar, Rita Ghosh. Food-based natural products for cancer management: Is the whole greater than the sum of the parts? Seminars in Cancer Biology 2016 Jan;40-41:233-246. Thanpa D., Ghosh R. Chronic inflammatory mediators enhance prostate cancer development and progression Biochemical Pharmacology 2015 Jan;94(2):53-62. Mukherjee N1, Houston TJ1, Cardenas E1, Ghosh R2. To be an ally or an adversary in bladder cancer: the NF-κB story has not unfolded Carcinogenesis 2015 Jan;36(3):299-306. Mukherjee N, Kumar AP, Ghosh R. DNA Methylation and Flavonoids in Genitourinary Cancers Curr Pharmacol Rep 2015 Jan;1(2):112-120.